首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?
【24h】

Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?

机译:心房纤颤患者开始口服抗凝剂抗凝治疗期间是否存在高凝阶段?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

INTRODUCTION: During commencement of oral anticoagulant therapy (OAT) a theoretical possibility of a transient hypercoagulable state emerges from the difference in plasma half-life between the vitamin K-dependent pro-coagulation factors II and X, and the vitamin K-dependent anticoagulant proteins C and S. In the present study, markers reflecting the activity in the haemostatic system (prothrombin fragment 1+2 [F1+2], D-dimer and soluble fibrin) was assessed during initiation of OAT compared to subcutaneously administered low-molecular weight heparin (LMWH) which does not cause any imbalance between the concentrations of the pro- and anticoagulation proteins. METHODS: Thirty-three patients with atrial fibrillation were randomly treated either with OAT (warfarin 10, 7.5, and 5 mg for three consecutive days) or LMWH administered in a fixed dose of 200 anti-Xa IU/kg body weight in one subcutaneous injection daily. The biochemical markers were measured at baseline, and after 12, 36 and 60 h of treatment. RESULTS AND CONCLUSIONS: After introducing antithrombotic therapy, none of the biochemical markers increased within the study period in the two treatment groups. The level of F1+2 had declined significantly at 60 h in both groups. The level of soluble fibrin showed a significant decrease within the first 60 h in the OAT group, and no significant changes were seen in the LMWH group. No significant change in the level of D-dimer was seen during the first 60 h of treatment in either group. Taken together, no transient hypercoagulable state could be identified within the first 60 h of commencing OAT in patients with atrial fibrillation.
机译:简介:在口服抗凝治疗(OAT)开始期间,理论上的可能性是由于维生素K依赖的促凝血因子II和X与维生素K依赖的抗凝蛋白之间的血浆半衰期不同而出现短暂的高凝状态C和S。在本研究中,与皮下给药低分子量药物相比,在OAT启动期间评估了反映止血系统活性的标志物(凝血酶原片段1 + 2 [F1 + 2],D-二聚体和可溶性血纤蛋白)。肝素(LMWH),不会在促凝蛋白和抗凝蛋白的浓度之间造成任何不平衡。方法:对33例房颤患者随机给予OAT(华法林10、7.5和5 mg,连续三天)或LMWH皮下注射,剂量固定为200抗Xa IU / kg体重日常。在基线以及治疗12、36和60小时后测量生化标志物。结果与结论:引入抗血栓治疗后,两个治疗组的生化指标在研究期内均未增加。两组中的F1 + 2水平在60 h时均显着下降。 OAT组在头60小时内可溶性血纤蛋白水平显着下降,而LMWH组未见明显变化。两组中在治疗的最初60小时内,D-二聚体水平均未见明显变化。两者合计,在房颤患者开始OAT的前60小时内未发现短暂的高凝状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号